

INTROGEN THERAPEUTICS INC

Form 8-K

July 23, 2008

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported)

**July 23, 2008 (July 22, 2008)**

---

**Introgen Therapeutics, Inc.**

(Exact name of registrant as specified in its charter)

<b>Delaware</b>	<b>0-21291</b>	<b>74-2704230</b>
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

**301 Congress Avenue, Suite 1850  
Austin, Texas 78701**

(Address of principal executive offices, including zip code)

**(512) 708-9310**

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

---

---

**Item 7.01 Regulation FD Disclosure.**

On July 22, 2008, Introgen Therapeutics, Inc. (“Introgen”) presented the results of additional statistical analyses of the data from the pivotal Phase 3 clinical trial of ADVEXIN in patients with recurrent, refractory head and neck cancer. Introgen presented these data at the American Association for Cancer Research (AACR) Centennial Conference on Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine. A copy of the press release announcing these results is attached hereto as Exhibit 99.1.

The information in this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

99.1 Press Release dated July 23, 2008.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTROGEN THERAPEUTICS, INC.

By: /S/ RODNEY VARNER.

Rodney Varner

Secretary

Date: July  
22,  
2008

---

**EXHIBIT INDEX**

**Exhibit No.   Description**

99.1            Press Release dated July 23, 2008.